The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease
Open accessAbstract
BACKGROUND: Cushing's disease is associated with high morbidity and mortality. Pasireotide, a potential therapy, has a unique, broad somatostatin-receptor-binding profile, with high binding affinity for somatostatin-receptor subtype 5. METHODS: In this double-blind, phase 3 study, we randomly assigned 162 adults with Cushing's disease and a urinary free cortisol level of at least 1.5 times the upper limit of the normal range to receive subcutaneous pasireotide at a dose of 600 μg (82 patients) or 900 μg (80 patients) twice daily. Patients with urinary free cortisol not exceeding 2 times the upper limit of the normal range and not exceeding the baseline level at month 3 continued to receive their randomly assigned dose; all others received an additional 300 μg twice daily. The primary end point was a urinary free cortisol level at or below the upper limit of the normal range at month 6 without an increased dose. Open-label treatment continued through month 12. RESULTS: Twelve of the 82 patients in the 600-μg group and 21 of the 80 patients in the 900-μg group met the primary end point. The median urinary free cortisol level decreased by approximately 50% by month 2 and remained stable in both groups. A normal urinary free cortisol level was achieved more frequently in patients with baseline levels not exceeding 5 times the upper limit of the normal range than in patients with higher baseline levels. Serum and salivary cortisol and plasma corticotropin levels decreased, and clinical signs and symptoms of Cushing's disease diminished. Pasireotide was associated with hyperglycemia-related adverse events in 118 of 162 patients; other adverse events were similar to those associated with other somatostatin analogues. Despite declines in cortisol levels, blood glucose and glycated hemoglobin levels increased soon after treatment initiation and then stabilized; treatment with a glucose-lowering medication was initiated in 74 of 162 patients. CONCLUSIONS: The significant decrease in cortisol levels in patients with Cushing's disease who received pasireotide supports its potential use as a targeted treatment for corticotropin-secreting pituitary adenomas. (Funded by Novartis Pharma; ClinicalTrials.gov number, NCT00434148.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mean UFC is routinely used in clinical practice and research to monitor disease control and treatment response in patients with CS treated with medical therapy (129-137).”
From Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement. (2026) · cites this paper as [136]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The restoration of cortisol circadian rhythm following medical therapy has not been investigated or established for most medications used to treat CS, and it is not routinely measured to determine treatment response (129-137).”
From Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement. (2026) · cites this paper as [136]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In clinical trials, the efficacy of steroidogenesis inhibitors and pituitary-directed therapies in patients with CS was primarily evaluated by the normalization of cortisol secretion per UFC (129-137).”
From Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement. (2026) · cites this paper as [136]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lacroix, A., Feelders, R. A., Stratakis, C. A., & Nieman, L. K. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61375-1 · Cited by 1,777
Diagnosis and complications of Cushing’s syndrome: a consensus statement
Arnaldi, G., Angeli, A., Atkinson, A. B., Bertagna, X., Cavagnini, F., Chrousos, G. P., Fava, G. A., Findling, J. W., Gaillard, R. C., Grossman, A. B., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030871 · Cited by 1,362
Self-citationNewell-Price, J. D. C., BERTAGNA, X. Y., Grossman, A. B., & Nieman, L. K. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68699-6 · Cited by 1,242
Self-citationTreatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement
Biller, B. M. K., Grossman, A. B., Stewart, P. M., Melmed, S., Bertagna, X., Bertherat, J., Buchfelder, M., Colao, A., Hermus, A. R., Hofland, L. J., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2734 · Cited by 853
Self-citationIncidence and Late Prognosis of Cushing's Syndrome: A Population-Based Study
Lindholm, J., Juul, S., Jørgensen, J. O. L., Astrup, J., Bjerre, P., Feldt‐Rasmussen, U., Hagen, C., Jørgensen, J. O. L., Kosteljanetz, M., Kristensen, L. Ø., et al. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.1.7093 · Cited by 763
Bruns, C., Lewis, I., Briner, U., Meno-Tetang, G., & Weckbecker, G. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1460707 · Cited by 692
Morbidity and mortality in Cushing's disease: an epidemiological approach.
Etxabe, J., & Vazquez, J. A. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb02486.x · Cited by 622
Incidence and Late Prognosis of Cushing's Syndrome: A Population-Based Study
Lindholm, J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.1.117 · Cited by 505
The Pathophysiological Consequences of Somatostatin Receptor Internalization and Resistance
Hofland, L. J., & Lamberts, S. W. J. (2003) · Endocrine Reviews · doi:10.1210/er.2000-0001 · Cited by 474
Pivonello, R., Martino, M. C. D., Cappabianca, P., Leo, M. D., Faggiano, A., Lombardi, G., Hofland, L. J., Lamberts, S. W. J., & Colao, A. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1533 · Cited by 328
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- Cavagnini F, 2001, Ann Endocrinol (Paris), 62, 168
Cited by
Sorted by citations
Items 601–625 of 625
Diabetes in Hypersecreting Endocrine Disorders
Vaag, A. A., Hanley, N. A., & Kistorp, C. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch22
Pituitary tumors, ACTH-secreting
Pivonello, R., Larocca, A., Simeoli, C., Paola, N. D., Crescenzo, E. M., & Colao, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00122-9
Self-citationLong-term complications of hypercortisolism
Pivonello, R., Crescenzo, E. M., Simeoli, C., Paola, N. D., Larocca, A., & Colao, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00123-0
Self-citationMedical therapy of pituitary adenomas
Molitch, M. E. (2024) · Brain medicine : · doi:10.61373/bm024i.0127
Editorial for Special Issue “Improving Outcome of Cushing’s Syndrome-4” (IMPROCUSH-4)
Reincke, M. (2024) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2462-6525
Advances in pharmacological treatment of Cushing's disease.
Chai, J., Tang, Y. J., Liu, Y., Tan, H., & Li, J. (2024) · PubMed Central · doi:10.11817/j.issn.1672-7347.2024.240306
Diagnosis and clinical management of aggressive pituitary tumors
Raverot, G., Jouanneau, E., Alcubierre, D. D., Carretti, A. L., & Trouillas, J. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00226-0
Baehring, J. M., Shih, H. A., Chen, Z., & Santagata, S. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780198869702.003.0023
Ferrière, A., & Tabarin, A. (2025) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2025.07.002
Kumar, S., Rawat, A., Sanapala, K., Alisha, K. A., Dhall, S., Prajapati, S. D., Patel, M. K., Das, A., Ramteke, H. D., & Khan, R. (2025) · medRxiv · doi:10.1101/2025.09.01.25334840
Popp, K. H., Buchfelder, M., & Stalla, G. K. (2025) · Elsevier eBooks · doi:10.1016/b978-3-437-21184-3.00001-6
Use of Pasireotide in Acromegaly: Clinical Experiences From a Series of Patients in Qatar
Elhadd, T. A., Dabbous, Z., Abdelmahmuod, E. A., Rohani, Z. S., & Alkailani, Y. (2025) · Case Reports in Endocrinology · doi:10.1155/crie/6400298
Nippoldt, T. B. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8684-8_5
Neoplasms of the Endocrine Glands: Pituitary Neoplasms
Gandhi, C. D., Pain, M., & Post, K. D. (2017) · Holland‐Frei Cancer Medicine · doi:10.1002/9781119000822.hfcm080
Hyperglycémie induite par l’analogue de somatostatine pasiréotide au cours de la maladie de Cushing
Reznik, Y., Bisot-Locard, S., & Vergès, B. L. (2015) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(15)30072-9
Zago, E., Citone, M., Canu, L., Antonuzzo, L., Pillozzi, S., Pellegrini, E., Petrone, L., Maggi, M., & Sparano, C. (2026) · Endocrine · doi:10.1007/s12020-025-04470-x
Medical therapies for Cushing’s syndrome
Pivonello, R., Paola, N. D., Simeoli, C., & Colao, A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-96100-4.00001-6
Self-citationCushing’s disease: Pituitary tumors causing CS—Diagnosis and treatment
Alcubierre, D. D., Kassi, E., Isidori, A. M., & Hasenmajer, V. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-96100-4.00010-7
Medical therapy of hypercortisolism
Feelders, R. A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00390-3
Zhao, Y., Tao, Y., Zhu, Y., Li, S., Guo, H., Huang, Y., Huang, Y., & Fang, C. (2026) · Endocrine · doi:10.1007/s12020-026-04560-4
Fedeli, F., Bistika, M., Ascione, F., Marangelo, A., Guzzi, F. L., Schrader, J., Harris, A. G., & Pellegata, N. S. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1766563
Newell-Price, J. D. C., Biller, B. M. K., Fleseriu, M., Gueron, B., Binowski, G., Packowska, A., & Gadelha, M. R. (2026) · Clinical Endocrinology · doi:10.1111/cen.70166
Self-citationKrylov, V. V., Usachev, D. Y., Grigoriev, A. Y., Cherebillo, V. Y., Kalinin, P. L., Kutin, M. A., Pashaev, B., Rudenko, P. G., Gormolysova, E., Dedov, I. I., et al. (2026) · Endocrine Surgery · doi:10.14341/serg13053
Cortisol in cardio-kidney-metabolic disease
Khan, M. S., Arshad, M. S., Bhatt, D. L., Cherney, D. Z. I., DeFronzo, R. A., Green, J. B., Handelsman, Y., Shafi, T., Testani, J. M., & Butler, J. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag827
Novità nella terapia medica della malattia di Cushing
Martin, M. D., & Giraldi, F. P. (2012) · L Endocrinologo · doi:10.1007/bf03346013
Metadata
- Authors
- Colao, A., Petersenn, S., Newell-Price, J., Findling, J. W., Gu, F., Maldonado, M., Schoenherr, U., Dipl.-Biol., Mills, D., Salgado, L. R., & Biller, B. M. K.
- Affiliations
- Federico II University Hospital (IT)
- University of Duisburg-Essen (DE)
- University of Sheffield (GB)
- Medical College of Wisconsin (US)
- Peking Union Medical College Hospital (CN)
- Novartis (Switzerland) (CH)
- Universidade de São Paulo (BR)
- Massachusetts General Hospital (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-03-08
- Volume
- 366
- Issue
- 10
- Pages
- 914-924
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2133418708
- Semantic Scholar
- d3443b929babd2daf7d6ae90395d546356fda173
- Cited by
- 628
- References
- 22
- Citations by year
- 2026: 13 · 2025: 31 · 2024: 28 · 2023: 28 · 2022: 33 · 2021: 35 · 2020: 32 · 2019: 41 · 2018: 46 · 2017: 46 · 2016: 52 · 2015: 66 · 2014: 68 · 2013: 77 · 2012: 29
- FWCI
- 61.61
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Scientific Electronic Library Online (São Paulo Research Foundation, Latin American and Caribbean Center on Health Sciences Information, Conselho Nacional de Desenvolvimento Científico e Tecnológico) (publishedVersion)
- HAL (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- pasireotide, Cushing's disease, somatostatin receptor type 5, somatostatin analogues, urinary free cortisol, hypercortisolism, hyperglycemia, HbA1c, dose escalation
- MeSH terms
- Adolescent, Adrenocorticotropic Hormone, Adult, Aged, Child, Double-Blind Method, Female, Humans, Hydrocortisone, Male, Middle Aged, Recurrence, Saliva, Somatostatin, Pituitary ACTH Hypersecretion, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
